Skip to content
  • Saturday, 12 September 2026
  • 6:39 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies
Pharmaceutical R&D

Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies

Teuku Ryan Apr 11, 2026 0

Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies Roche, a global pharmaceutical giant,…

Read More
Pharmaceutical R&D

The Rise of Antibody-Drug Conjugates: Precision Oncology’s Evolving Frontier

Teuku Ryan Mar 31, 2026 0

Antibody-drug conjugates (ADCs) represent a significant leap forward in targeted cancer therapy, a sophisticated class of drugs that marries the…

Read More
Sensory Basis of Speech Motor Learning and Memory: A New Paradigm in Human NeuroscienceFDA Reverses Course, Agrees to Review Moderna’s mRNA Flu VaccinePenn Researchers Develop Breakthrough Non-Addictive Gene Therapy Targeting Brain Pain Circuits to Combat Chronic Pain and Opioid CrisisMolecular Mechanism of Sperm Morphogenesis Revealed Through TEX38 and ZDHHC19 Protein Interaction
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
The oral exposure challenge in PROTACs: What drug developers need to solve earlyAttention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Sep 12, 2026
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ